A 62-year-old man with diabetes mellitus presents with fever, dysuria, and flank pain. Urine culture grows an Escherichia coli isolate resistant to ceftriaxone and cefotaxime but susceptible to carbapenems and fluoroquinolones. ESBL production is confirmed by the double-disk synergy test. What is the drug of choice for treatment of this ESBL-producing E. coli urinary tract infection?

## ESBL-Producing Gram-Negative Infections: Drug Selection **Key Point:** Carbapenems (meropenem, ertapenem, imipenem) are the drugs of choice for serious infections caused by ESBL-producing Enterobacteriaceae. They are resistant to hydrolysis by ESBLs and provide reliable bactericidal activity. ### Why Meropenem is Correct Meropenem is a broad-spectrum carbapenem with: - Excellent activity against ESBL-producing E. coli - Beta-lactamase stability (not hydrolyzed by ESBLs) - Good tissue penetration, including into urine - Proven clinical efficacy in UTIs, sepsis, and intra-abdominal infections caused by resistant gram-negatives **High-Yield:** Carbapenems remain the gold standard for ESBL-producing organisms because their beta-lactam ring structure is resistant to ESBL hydrolysis. ### Treatment Algorithm for ESBL Infections ```mermaid flowchart TD A[ESBL-producing gram-negative isolated]:::outcome --> B{Severity & Site of Infection}:::decision B -->|Uncomplicated UTI, susceptible to FQ| C[Fluoroquinolone or Nitrofurantoin]:::action B -->|Complicated UTI, sepsis, or serious infection| D[Carbapenem]:::action D --> E[Meropenem 1g IV/IM TDS]:::action E --> F[Clinical improvement in 48-72 hrs]:::outcome B -->|Mild infection, oral option needed| G[Consider fluoroquinolone if susceptible]:::action ``` ### Comparative Drug Efficacy Table | Drug Class | Agent | ESBL Resistance | Suitable for ESBL? | Notes | |---|---|---|---|---| | 3rd-gen Cephalosporin | Ceftriaxone | Hydrolyzed by ESBL | **No** | Predictable failure; not recommended | | 3rd-gen Cephalosporin | Cefixime | Hydrolyzed by ESBL | **No** | Oral form; still susceptible to ESBL | | Carbapenem | Meropenem | Resistant to ESBL | **Yes** | First-line for serious infections | | Fluoroquinolone | Ciprofloxacin | Variable resistance | Conditional | Only if susceptibility confirmed; uncomplicated UTI only | **Clinical Pearl:** Although ciprofloxacin may show in vitro susceptibility, fluoroquinolones are reserved for uncomplicated UTIs or mild infections in ESBL-producing organisms. For systemic or complicated infections (as in this case with flank pain suggesting pyelonephritis), carbapenems are mandatory. **Mnemonic:** **CARBAPENEM RULE** — **C**arbapenems **A**re **R**esistant to **B**eta-lactamase **A**nd **P**erfect for **E**SBL **N**egatives **E**ntering **M**ajor infections.